Results 171 to 180 of about 128,101 (191)
Some of the next articles are maybe not open access.
Targeting BET bromodomains in hematological malignancies
Hématologie, 2017Les proteines a bromodomaines de la famille BET (pour bromodomain and extra terminal domain) modulent l’expression genique en regulant le controle de l’elongation transcriptionnelle par des elements regulateurs distaux, ou enhancers. Des etudes de criblage fonctionnel et la synthese d’inhibiteurs chimiques ont revele l’importance des proteines BET dans
Justine Penneroux, Raphael Itzykson
openaire +1 more source
Role of bromodomain and extraterminal (BET) proteins in prostate cancer
Expert Opinion on Investigational Drugs, 2023Mark C Markowski +2 more
exaly
BETting on next-generation bromodomain inhibitors.
American journal of clinical and experimental urologyWithin the last decade, bromodomain and extraterminal (BET) domain inhibitors were introduced as the first in a wave of new agents known as bromodomain inhibitors. These original examples exhibited anti-inflammatory and anticancer properties, and some have progressed to human clinical trials.
Matthew K, Collins +3 more
openaire +1 more source
BET bromodomain inhibitors: a patent review
Expert Opinion on Therapeutic Patents, 2014Christopher J. Burns, Phillip P. Sharp
exaly
BET bromodomain proteins regulate enhancer function during adipogenesis
Proceedings of the National Academy of Sciences of the United States of America, 2018Jaime M Reyes +2 more
exaly
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer
Cancer Letters, 2017Ana Sofia Mendes Leal +2 more
exaly
Tetrahydroquinoline compositions as BET bromodomain inhibitors
2015BAIR KENNETH W +8 more
openaire +9 more sources